Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 2 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

0
Player Avatar catfam (< 20) Submitted: 10/13/2012 4:46:33 PM : Outperform Start Price: $0.73 PPHM Score: +64.10

approval of products

Featured Broker Partners


Advertisement